Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
2019-08-16 08:00:18
Oslo, Norway, 16 August 2019 Nordic Nanovector ASA (OSE: NANO) announces that it will report its results for the second quarter and first half 2019 on Thursday, 22 August 2019. A presentation by Nordic Nanovector's senior management team will take place at 8:30am CEST at: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo Meeting Room: AKER The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investors & Media The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2019 from 7:00am CEST the same day. For further information, please contact: IR enquiries Malene Brondberg, VP Investor Relations and Corporate Communications Cell: +44 7561 431 762 Email: ir@nordicnanovector.com Media Enquiries Mark Swallow/David Dible (Citigate Dewe Rogerson) Tel: +44 207 638 9571 Email: nordicnanovector@citigatedewerogerson.com About Nordic Nanovector: Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37 -targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com. This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act.